Why the study?
The study investigated the effect of aspirin on colorectal cancer risk among subgroups of women with and without risk factors for colorectal cancer.
Does aspirin reduce colorectal cancer risk in women across different subgroups of cardiovascular and colorectal cancer risk factors?
Does aspirin reduce colorectal cancer risk in women across different subgroups of cardiovascular and colorectal cancer risk factors?
Aspirin use is associated with a reduced risk of colorectal cancer in women regardless of cardiovascular risk status, though the benefit appears limited to those without a family history of CRC or those with a history of polypectomy.
Answers are grounded in this paper and cite their sources.
Should not yet inform aspirin use for CRC prevention; extends observational data to CVD-risk subgroups but remains hypothesis-generating.
BACKGROUND/AIM: We investigated the effect of aspirin on colorectal cancer (CRC) risk among subgroups of women with and without risk factors for CRC. PATIENTS AND METHODS: Using data from the Women's Health Initiative, we estimated hazard ratios for CRC in association with aspirin use, with stratifications by cardiovascular disease (CVD) risk status, family history of CRC, and history of colorectal polypectomy. RESULTS: Aspirin was associated with a lower risk of CRC among women with low/normal or high CVD-risk status; no family history of CRC; or a history of colonoscopy with polypectomy. Aspirin was not associated with CRC among women with a family history of CRC or a history of colonoscopy without polypectomy. CONCLUSION: Aspirin was associated with a lower risk of CRC in women at all levels of CVD-risk, in those with a history of colonoscopy with polypectomy, and in those without a family history of CRC.
No takes yet. Share an insight, caveat, or question.
Seaton et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: